Abstract
Background: The relation between cannabis use and psychotic disorders has been investigated extensively. A series of metaanalytic reviews reveal a robust association between cannabis use and the development of psychosis and schizophrenia. However, the actual impact of cannabis use in subjects at high clinical risk for psychosis (CHR) is still unclear.
Method: We conducted a systematic review of publications measuring the impact of cannabis use on CHR symptomatology and transition to a first psychotic episode.
Results: Of 729 potentially relevant papers, 11 met inclusion criteria. The results of these studies were mixed. In some studies, cannabis use was associated with more severe symptoms at baseline, increased pre-psychotic symptoms immediately after intoxication, and earlier onset of certain high-risk symptoms. In others, no significant association between cannabis use and baseline symptomatology was found. In one study, cannabis use was even significantly associated with a decrease in pre-psychotic negative symptoms, and with fewer symptoms of depression and anxiety. Four out of 5 studies reported no significant effect of cannabis use on transition to psychosis.
Conclusions: Cannabis use seems to provoke and enhance subclinical symptoms in CHR subjects. However, the results provide no consistent evidence for an association between cannabis use and transition to a first psychosis in CHR subjects.
Keywords: Prodrome, ultra high-risk, prodromal symptoms, cannabis, transition, psychosis
Current Pharmaceutical Design
Title:Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis
Volume: 18 Issue: 32
Author(s): Floor J. van der Meer, Eva Velthorst, Carin J. Meijer, Marise W.J. Machielsen and Lieuwe de Haan
Affiliation:
Keywords: Prodrome, ultra high-risk, prodromal symptoms, cannabis, transition, psychosis
Abstract: Background: The relation between cannabis use and psychotic disorders has been investigated extensively. A series of metaanalytic reviews reveal a robust association between cannabis use and the development of psychosis and schizophrenia. However, the actual impact of cannabis use in subjects at high clinical risk for psychosis (CHR) is still unclear.
Method: We conducted a systematic review of publications measuring the impact of cannabis use on CHR symptomatology and transition to a first psychotic episode.
Results: Of 729 potentially relevant papers, 11 met inclusion criteria. The results of these studies were mixed. In some studies, cannabis use was associated with more severe symptoms at baseline, increased pre-psychotic symptoms immediately after intoxication, and earlier onset of certain high-risk symptoms. In others, no significant association between cannabis use and baseline symptomatology was found. In one study, cannabis use was even significantly associated with a decrease in pre-psychotic negative symptoms, and with fewer symptoms of depression and anxiety. Four out of 5 studies reported no significant effect of cannabis use on transition to psychosis.
Conclusions: Cannabis use seems to provoke and enhance subclinical symptoms in CHR subjects. However, the results provide no consistent evidence for an association between cannabis use and transition to a first psychosis in CHR subjects.
Export Options
About this article
Cite this article as:
J. van der Meer Floor, Velthorst Eva, J. Meijer Carin, W.J. Machielsen Marise and de Haan Lieuwe, Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884762
DOI https://dx.doi.org/10.2174/138161212802884762 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Childhood Hospitalisations for Physical Disease and Risk of Mental Disorders During Adolescence and Early Adulthood
Adolescent Psychiatry Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology Scutellaria barbata Flavonoids Improve the Composited Aβ-induced Abnormal Changes in Glial Cells of the Brains of Rats
Combinatorial Chemistry & High Throughput Screening Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Physiotherapy for Ankylosing Spondylitis: Systematic Review and a Proposed Rehabilitation Protocol
Current Rheumatology Reviews A Review on Recent Robotic and Analytic Technologies in High Throughput Screening and Synthesis for Drug Discovery
Letters in Drug Design & Discovery Synthesis of Novel 2-(Methylthio)benzo[g][1,2,4]triazolo[1,5-a]quinazolin- 5-(4H)-one and its Derivatives
Letters in Organic Chemistry Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets Aging in the Perspective of Integrative Medicine, Psychoneuroendocrineimmunology and Hormesis
Current Aging Science Diabetes NEP-Like Endopeptidases and Alzheimers Disease
Current Alzheimer Research Regulation of Catalysis Within Cellular Network: Metabolic and Signaling Implications of the 2-Oxoglutarate Oxidative Decarboxylation
Current Chemical Biology Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management
Current Medicinal Chemistry Cultivating a Trauma Awareness Culture in the Addictions
Current Drug Abuse Reviews Application of Simplex Optimization in the Development of an On-line Preconcentration System for the Determination of Cu in Human Hair Samples Using FAAS
Current Analytical Chemistry D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Recombinant Interleukin-12 for Immunotherapy: A Double-Sided Sword
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents